Advertisement

Leukemia

Inotuzumab Ozogamicin Shows Clear Benefit in Acute Lymphoblastic Leukemia

In patients with relapsed/refractory acute lymphoblastic leukemia (ALL), the antibody-drug conjugate inotuzumab ozogamicin produced...

Health-Care Policy

How the Oncology Center of Excellence Plans to Foster Collaboration Among Researchers to Advance Cancer Treatment

On June 29, 2016, Robert M. Califf, MD, MACC, the Commissioner of the U.S. Food and Drug Administration (FDA), announced the selection...

Issues in Oncology

Have You Received Your Immune Checkpoint Inhibitor Yet?

“Have you received your immune checkpoint inhibitor yet?” I suspect St. Peter may have started asking this question routinely at the...


Advertisement

More Top Stories

CNS Cancers

James R. Perry, MD, on Glioblastoma: Study Results on Treating Elderly Patients

Rajeswari Nagarathinam, MD, Joins Department of Pathology at Fox Chase Cancer Center

Rajeswari Nagarathinam, MD, has joined the Department of Pathology at Fox Chase Cancer Center, focusing on both surgical pathology and cytopathology. Dr. Nagarathinam is currently completing a surgical oncologic pathology fellowship at Fox Chase.

Dr. Nagarathinam is a licensed, board-certified...

Advertisement

Overall Survival With Bevacizumab/Capecitabine Noninferior vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer

As reported in The Lancet Oncology by Zielinski et al, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine was noninferior vs bevacizumab/paclitaxel in per-protocol analysis among patients with advanced HER2-negative...

Lymphoma

Jonathan W. Friedberg, MD: Marginal Zone Lymphoma Therapy Update

Issues in Oncology
Health-Care Policy

Moonshots and ‘Onco-nauts’

Where were you on July 20, 1969? I certainly remember where I was—sitting in a mess hall at summer camp watching a grainy black-and-white TV as Neil Armstrong took “one small step for man, one giant leap for mankind.” I recall the sense of jubilation and accomplishment that all American citizens...

Lymphoma

CAR T-Cell Therapy Promising in Non-Hodgkin Lymphoma

Research conducted at the Fred Hutchinson Cancer Research Center, Seattle, is moving the field of chimeric antigen receptor (CAR) T-cell therapy forward in the treatment of B-cell malignancies. At the 2016 Pan Pacific Lymphoma Conference in Koloa, Hawaii, David G. Maloney, MD, PhD, Professor of...

Study Finds Effect of Combined Hormone Replacement Therapy on Breast Cancer Risk Likely to Have Been Underestimated

The effect of combined hormone replacement therapy (HRT) in increasing a woman’s risk of breast cancer is likely to have been underestimated by a number of previous studies, according to a new prospective study published by Jones et al in the British Journal of Cancer.

HRT is used to treat...

Bladder Cancer

Arjun Vasant Balar, MD, on Urothelial Carcinoma: Analysis of the IMvigor210 Cohort 1

ASH Commits $3 Million Annually to Help Preserve Critical Blood Disease Research

With a $3 million annual commitment to support promising blood disease research amid limited National Institutes of Health (NIH) funding, the American Society of Hematology (ASH) has announced the formal establishment of the ASH Bridge Grant program after an extended 4-year pilot study.

ASH also...

Advertisement

Increased Uveal Melanoma Risk Linked to Pigmentation Genes That Dictate Eye Color

New research links specific inherited genetic alterations to an increased risk for uveal melanoma, a rare form of melanoma that arises from pigment cells that determine eye color. These findings were published by Ferguson et al in Scientific Reports.

Previous clinical data suggests uveal melanoma...